A PRIM approach to predictive-signature development for patient stratification

Statistics in Medicine

Volumn 34, Issue 2, 2015, Pages 317-342

  Chen, Gong ^a   Zhong, Hua ^b   Belousov, Anton ^c   Devanarayan, Viswanath ^d  

^a Roche Pharma Research and Early Development Roche Innovation Center New York Roche TCRC Inc   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROCHE INNOVATION CENTER MUNICH   (Germany)

^d ABBVIE INC   (United States)

Author keywords

Biomarker; Patient rule induction method (PRIM); Patient stratification; Predictive signature; Subgroup analysis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; TAMOXIFEN; VINCRISTINE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ESTROGEN RECEPTOR;

ALGORITHM; ARTICLE; BREAST CARCINOMA; EFFECT SIZE; HUMAN; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; PATIENT CARE; PATIENT RULE INDUCTION METHOD; PATIENT STRATIFICATION; PREVALENCE; RECURRENCE FREE SURVIVAL; SAMPLING; SIMULATION; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHODOLOGY; MICROARRAY ANALYSIS; NEOPLASMS; OUTCOME ASSESSMENT; PATIENT SELECTION; PHARMACOGENETICS; PREDICTIVE VALUE; PROCEDURES; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; BIOMARKERS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROARRAY ANALYSIS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 84916228481     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6343     Document Type: Article

References (19)

1. Friedman JH, Fisher NI. Bump hunting in high-dimentional data. Statistics and Computing 1999; 9:123-143.
2. LeBlanc M, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. Statistical Methods in Medical Research 2002; 11:247-274.
3. LeBlanc M, Moon J, Crowley J. Adaptive risk group refinement. Biometrics 2005; 61:370-378.
4. Liu X, Minin V, Huang Y, Seligson DB, Horvath S. Statistical methods for analyzing tissue microarray data. Journal of Biopharmaceutical Statistics 2004; 14(3):671-685.
5. Dyson G, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A, Sing CF. An application of the patient rule-induction method for evaluating the contribution of the Apolipoprotein E and Lipoprotein Lipase genes to predicting ischemic heart disease. Genetic Epidemiology 2007; 31:515-527.
6. Nannings B, Abu-Hanna A, deJonge E. Applying PRIM (patient rule induction method) and logistic regression for selecting high-risk subgroups in very elderly ICU patients. International Journal of Medical Informatics 2008; 77:272-279.
7. Polonik W, Wang Z. PRIM analysis. Journal of Multivariate Analysis 2010; 101:525-540.
8. Kehl V, Ulm K. Responder identification in clinical trials with censored data. Computational Satistics and Data Analysis 2006; 50:1338-1355.
9. Tian L, Tibshirani R. Adaptive index models for marker-based risk stratification. Biostatistics 2011; 12(1):68-86.
10. Lin X, Parks D, Cheng J, Lee K. Searching for clinically interesting subgroups using patient rule induction method. 24c. Eastern North American Region (ENAR) Spring Meeting, Miami, Florida, 2011.
11. Mitchell TM. Machine Learning. McGraw-Hill: New York, 1997.
12. Hastie T, Tibshirani RJ, Friedman J. The Elements of Statistical Learning: Data Mining, Inference and Prediction Second. Springer: New York, 2008.
13. Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search-a recursive partitioning method for establishing response to treatment in patient subpopulations. Statistics in Medicine 2011; 30:2601-2621.
14. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, J Bergh, JA, Foekens. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 2007; 25(10):1239-1246.
15. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, J, Iqbal. et al. Stromal gene signatures in large-B-cell lymphomas. The New England Journal of Medicine 2008; 359(1):2313-2323.
16. Tibshirani RJ, Efron B. Pre-validation and inference in microarrays. Statistical Applications in Genetics and Molecular Biology 2002; 1(1):1-18.
17. Negassa A, Ciampi A, Abrahamowicz M, Shapiro S, Boivin J. Tree-structured subgroup analysis for censored survival data: validation of computationally inexpensive model selection criteria. Statistics and Computing 2005; 15:231-239.
18. Su X, Tsai C, Wang H, Nickerson DM, Li B. Subgroup analysis via recursive partitioning. Journal of Machine Learning Research 2009; 10:141-158.
19. Foster JC, Taylor JMG, Ruberg SJ. Subgroup identification from randomized clinical trial data. Statistics in Medicine 2011; 30:2867-2880.